Delving into the Latest Updates on Carvedilol with Synapse

Overview

Basic Info

SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions.

Drug Type

Small molecule drug

Synonyms

Carvedilol (JP17/USP/INN), Corever, Pluscor

+ [28]

Target

ADRA1 x adrenergic receptor x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

+ [1]

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesUrogenital Diseases

Active Indication

Atrial FibrillationAngina, StableHeart Failure+ [5]

Inactive Indication

Chronic heart failureDrug Resistant EpilepsyHypertrophy, Left Ventricular+ [3]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

InnoPharmax, Inc.Alvogen Korea Co., Ltd.

Daiichi Sankyo Co., Ltd.

+ [1]

Inactive Organization

TSH Biopharm Corp., Ltd.

Chong Kun Dang Pharmaceutical Corp.

GSK Plc

+ [1]

Drug Highest PhaseApproved

First Approval Date

JP (19 Jan 1993),

Angina PectorisEssential HypertensionHypertension, Renal

Regulation-

Login to view timeline

Structure

Molecular FormulaC24H26N2O4

InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N

CAS Registry72956-09-3

The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol non-responders. It will also learn about the safety of carvedilol combined with EVL in patients with cirrhosis.
The main questions it aims to answer are:
Whether carvedilol plus EVL is more effective than carvedilol alone in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.
What medical problems do participants have when taking carvedilol or taking carvedilol combined with undergoing EVL? Researchers will compare the efficacy and safety of carvedilol with or without EVL in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.
Participants will:
Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol, or Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Visit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.

Start Date01 Oct 2024

Sponsor / Collaborator

Taipei Veterans General Hospital

NCT06566794 / Not yet recruitingNot ApplicableIIT

KF2022#4-tutkimus:Beetasalpaajan ja tulehduskipulääkkeen Vaikutus CYP-entsyymivälitteiseen lääkeainemetaboliaan

Carvedilol is a non-selective beta-blocker in common clinical use, used to treat hypertension, heart failure, and angina pectoris symptoms associated with coronary artery disease. Diclofenac is a non-selective anti-inflammatory drug in general use, which is used to treat rheumatic diseases, osteoarthritis, musculoskeletal pain conditions, menstrual pains and migraines, among others. In our recent experiments involving liver cell enzymes, both carvedilol and diclofenac were found to inhibit several cytochrome P450 (CYP) enzymes central to drug metabolism, potentially leading to adverse drug interactions with other drugs metabolized by the same enzyme. The purpose of this study is to investigate the effects of the use of carvedilol and diclofenac on the activity of key CYP enzymes in drug metabolism in healthy volunteers using a low-dose model drug combination covering seven CYP enzymes.
In an open three-phase, randomized, crossover study with 12 healthy volunteers, the subjects will receive a drug combination of caffeine, bupropion, repaglinide, flurbiprofen, omeprazole, dextromethorphan, midazolam and simvastatin and as a premedication either placebo, carvedilol or diclofenac. Blood samples will be collected and carvedilol, diclofenac, caffeine, bupropion, repaglinide, flurbiprofen, omeprazole, dextromethorphan, midazolam and simvastatin pharmacokinetics will be monitored up to 23 hours post dose.

Start Date20 Aug 2024

Sponsor / Collaborator

Helsinki University Central Hospital

[+1]

100 Clinical Results associated with Carvedilol

Login to view more data

100 Translational Medicine associated with Carvedilol

Login to view more data

100 Patents (Medical) associated with Carvedilol

Login to view more data

3,828

Literatures (Medical) associated with Carvedilol

01 Dec 2024·Molecular Biology Reports

Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics

Review

Author: Beura, Samir K ; HariKrishnaReddy, Dibbanti ; Singh, Sunil K ; Sharma, Prajjwal ; Dhapola, Rishika

Alzheimer's disease's pathophysiology is still a conundrum. Growing number of evidences have elucidated the involvement of oxidative stress in the pathology of AD rendering it a major target for therapeutic development. Reactive oxygen species (ROS) generated by altered mitochondrial function, dysregulated electron transport chain and other sources elevate aggregated Aβ and neurofibrillary tangles which further stimulating the production of ROS. Oxidative stress induced damage to lipids, proteins and DNA result in neuronal death which leads to AD. In addition, oxidative stress induces apoptosis that is triggered by the modulation of ERK1/2 and Nrf2 pathway followed by increased GSK-3β expression and decreased PP2A activity. Oxidative stress exaggerates disease condition by interfering with various signaling pathways like RCAN1, CREB/ERK, Nrf2, PP2A, NFκB and PI3K/Akt. Studies have reported the role of TNF-α in oxidative stress stimulation that has been regulated by drugs like etanercept increasing the level of anti-oxidants. Other drugs like pramipexole, memantine, carvedilol, and melatonin have been reported to activate CREB/RCAN1 and Nrf2 pathways. In line with this, epigallocatechin gallate and genistein also target Nrf2 and CREB pathway leading to activation of downstream pathways like ARE and Keap1 which ameliorate oxidative stress condition. Donepezil and resveratrol reduce oxidative stress and activate AMPK pathway along with PP2A activation thus promoting tau dephosphorylation and neuronal survival. This study describes in detail the role of oxidative stress in AD, major signaling pathways involving oxidative stress induced AD and drugs under development targeting these pathways which may aid in therapeutic advances for AD.

01 Dec 2024·Molecular Biology Reports

Carvedilol induces pyroptosis through NLRP3-caspase1-ASC inflammasome by nuclear migration of NF-κB in prostate cancer models

Article

Author: Zeng, Yan ; Li, Mei-Xi ; Xu, Chen ; Wu, Shi-Qi

BACKGROUNDPyroptosis is an inflammatory type of programmed cell death, and could overcome the drug-resistance induced by anti-apoptotic effect of cancers. Carvedilol (CVL), a β-adrenergic receptors antagonist, has shown anti-inflammatory response and anti-cancer effect. The aim of this study is to investigate whether pyroptosis can be activated by CVL in prostate cancer (PCa).METHODS AND RESULTSDatasets were used to analyze the expressions of pyroptosis-related proteins. Intracellular morphological change, cell viability, LDH and Il-1β release by cells,, and Hoechst/PI staining were used to detect the occurrence of pyroptosis. Realtime-PCR, western blot, immunofluorescence, and immunohistochemistry (IHC) were used to investigate the expressions of pyroptosis-related proteins. Datasets analyze showed the expressions of NLRP3, Caspase 1, ASC and GSDMD were all decreased in PCa comparing with normal tissues, but without prognostic significance. CVL treatment weakened the viabilities of PCa cells. Cell morphology changing, cytoplasmic vacuole formation, membrane integrity loss, LDH and IL-1β release and PI positive cells increasing were observed. NLRP3, Caspase 1, ASC, GSDMD and N-GSDMD expressions were elevated after CVL treatment, accompanied by a tendency of NF-κB transferring into nucleus. In vivo, CVL inhibited the growth of subcutaneous transplanted tumor. IHC showed CVL increased the expressions of NLRP3, ASC, and GSDMD, and decreased the expression of Ki-67 in transplanted tumor tissues.CONCLUSIONThis study demonstrated that CVL could induce pyroptosis in PCa cells through NLRP3-caspase1-ASC inflammasome by promoting nuclear translocation of NF-κB, which would lay a foundation for the application of adrenergic receptor antagonist in PCa.

01 Dec 2024·Biochemical Pharmacology

Carvedilol through ß1-Adrenoceptor blockade ameliorates glomerulonephritis via inhibition of oxidative stress, apoptosis, autophagy, ferroptosis, endoplasmic reticulum stress and inflammation

Article

Author: Cheng, Yu-Hsuan ; Hsu, Shih-Ping ; Chien, Chiang-Ting ; Lin, Wei-Yu ; Lin, San-Chi ; Liu, Pei-Yu

Glomerulonephritis (GN) is one of the main causes of end stage renal disease and requires an effective treatment for inhibiting GN. Renal nerves through efferent (RENA) and afferent (RANA) innervation to glomeruli regulate the glomerular function. We delineated the role of RENA and RANA on anti-Thy1.1-induced GN. Female Wistar rats were divided into Control, Thy1.1 plus anti-Thy1.1, bilaterally renal nerve denervation (DNX) plus anti-Thy1.1, and topical capsaicin to bilateral renal nerves for selective ablation of RANA (DNAX) plus anti-Thy1.1. We examined RANA and RENA response to anti-Thy1.1 and compared the effect of DNX or DNAX on urinary oxidative stress, renal gp91, tyrosine hydroxylase (TH), calcitonin gene-related peptide (CGRP), apoptosis, autophagy, ferroptosis, antioxidant enzymes, endoplasmic reticulum (ER) stress and inflammation by western blot. Anti-Thy1.1 significantly enhanced RENA, but did not affect RANA. DNX significantly decreased TH and CGRP expression, whereas DNAX only reduced CGRP expression. Anti-Thy1.1 significantly increased glomerulosclerosis injury, urinary protein, electron paramagnetic resonance signals of alpha-(4-pyridyl-N-oxide)-N-tert-butylnitrone adducts, 8-isoprostane and nitrotyrosine levels, NADPH oxidase gp91phox (gp91), macrophage/monocyte (ED-1), GRP-78, Beclin-1/LC3-II, Bax/caspase-3/poly(ADP-ribose) polymerase expression, inflammatory cytokines levels and decreased renal Copper/Zinc superoxide dismutase, Cystine/glutamate transporter (xCT) and Glutathione peroxidase 4 (GPX4) expression vs. Control. The enhanced oxidative parameters or reduced antioxidant defense by anti-Thy1.1 were significantly attenuated by DNX but not DNAX. Additionally, oral ß1-adrenoceptor antagonist-Carvedilol at an early stage reduced anti-Thy1.1 increased proteinuria level and oxidative parameters. Our data suggest that DNX and ß1-adrenoceptor antagonist-Carvedilol efficiently attenuate oxidative stress, inflammation, ER stress, autophagy, ferroptosis and apoptosis in GN.

17

News (Medical) associated with Carvedilol

15 Feb 2024

·www.businesswire.com

GoodRx Now Offering 30 Common Heart Health Medications for Under $30

SANTA MONICA, Calif.--( BUSINESS WIRE )-- GoodRx , the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide. 1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That’s why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and brand-name medications that mitigate the risk and impact of cardiovascular conditions such as coronary artery disease, high cholesterol, hypertension, and more. By helping people afford their prescriptions, GoodRx is improving health outcomes and reducing the overall strain on the healthcare system. GoodRx’s recent report - The GoodRx Effect - estimates that GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits and 110,000 hospitalizations for major adverse cardiovascular events like heart attack and stroke. Save an average of 84% on common generic medications 2 The following is a sample list of common generic medications used to treat cardiovascular disease that are available for under $30 on GoodRx. MEDICATION LOWEST PRICE 3 AVG % SAVINGS 4 ACE Inhibitors Lisinopril (generic Prinivil and Zestril) $9.29 67% Enalapril (generic Epaned and Vasotec) $15.54 75% Beta Blockers Carvedilol (generic Coreg) $10.68 75% Metoprolol ER (generic Toprol XL) $11.15 74% Propranolol (generic Inderal) $10.96 71% Calcium Channel Blockers Amlodipine (generic Amvaz, Katerzia, and Norvasc) $9.15 80% Diltiazem ER (generic Cardizem CD) $13.43 74% Statins Atorvastatin (generic Lipitor) $10.10 83% Pravastatin (generic Pravachol) $14.53 74% Rosuvastatin (generic Crestor) $10.57 91% Access exclusive discounts and savings on brand-name drugs GoodRx offers incredible savings on brand-name medications that are often more costly and harder to obtain: MEDICATION SAVINGS* Entresto Pay as little as $10 for up to a 90-day supply Jardiance Pay as little as $10 per month Lodoco Pay as little as $30 for up to a 90-day supply Ozempic Pay as little as $25 per month Repatha Pay as little as $5 per month Soaanz Exclusive discount to save over 70% Toprol XL Exclusive discount to save up to 51% Xarelto Pay as little as $10 per fill *May require private or commercial insurance Learn more about cardiovascular disease from trusted doctors, pharmacists and health experts GoodRx Health is a go-to resource for understanding common heart conditions, risk factors, treatment options and associated savings. The GoodRx Heart Health Center provides credible, timely and actionable information to help people better manage their health. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more. “Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD , Medical Editor at GoodRx. “Knowledge is power, so we create easy-to-understand content that people can actually use so they are better equipped to minimize the risk of disease, find affordable medications, stick to their treatment plans, and ultimately improve their overall health and wellbeing.” To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com/hearthealth . About GoodRx GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade. GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com . We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers, the U.S. healthcare system and GoodRx; and GoodRx’s plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. 1 Prices are subject to change at any time without notice. Prices may vary at different pharmacies, and for different forms, dosages, and quantities. 2 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023. 3 As of February 1, 2024. 4 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023.

AHA

12 Jan 2024

·www.drugs.com

Carvedilol May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

12 Jan 2024

·www.drugs.com

Drug May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

100 Deals associated with Carvedilol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00255	Carvedilol	C07AG02	DB01136

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Atrial Fibrillation	JP	Daiichi Sankyo Co., Ltd.	24 Aug 2015
Angina, Stable	KR	Alvogen Korea Co., Ltd.	06 Nov 2001
Heart Failure	US	Waylis Therapeutics LLC	14 Sep 1995
Hypertension	US	Waylis Therapeutics LLC	14 Sep 1995
Ventricular Dysfunction, Left	US	Waylis Therapeutics LLC	14 Sep 1995
Angina Pectoris	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Essential Hypertension	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Hypertension, Renal	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Phase 3	TW	InnoPharmax, Inc.	12 Aug 2022
Ventricular Dysfunction, Left	Phase 3	TW	InnoPharmax, Inc.	12 Aug 2022
Drug Resistant Epilepsy	Phase 1	US	GSK Plc	01 Dec 2008
Atrial Fibrillation	Discovery	KR	Chong Kun Dang Pharmaceutical Corp.	23 Apr 2019
Essential Hypertension	Discovery	KR	Chong Kun Dang Pharmaceutical Corp.	01 Dec 2012
Pulmonary Arterial Hypertension	Discovery	US	GSK Plc	01 Jun 2010
Hypertension	Discovery	US	GSK Plc	01 Jan 2005
Hypertrophy, Left Ventricular	Discovery	US	GSK Plc	01 Jan 2005
Chronic heart failure	Discovery	US	GSK Plc	01 Jan 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Coronary Vasospasm	-	Carvedilol 2.5mg/kg	bbafadbvwy(nwrxddvaui) = wlqwwfaodz yuwvmbfnig (fmgdqghvoi )	-	30 Aug 2024
				Propranolol 20mg/kg	bbafadbvwy(nwrxddvaui) = vrkbjnumyl yuwvmbfnig (fmgdqghvoi )
NCT03069339 (CAVARLY, Pubmed) Manual	Not Applicable	Esophageal and Gastric Varices \| Liver Cirrhosis	330	Combination of carvedilol and VBL	nfsylblwnl(eqqasuxwxj) = juefbygxrx lfhtqndipq (fznrjinysu ) View more	Positive	27 Jul 2024
NCT00430040 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Inflammation \| Hypertension \| stress oxidative	14	lisinopril+Carvedilol Controlled Release (CR) (Carvedilol)	ipqvhhjnnf(pnmbuuhofn) = navydhsfms mbrmetszdh (opjihidsfx, tfjbsczgpy - knthhqxlri) View more	-	16 Apr 2024
				lisinopril (Lisinopril)	ipqvhhjnnf(pnmbuuhofn) = slulydcwwf mbrmetszdh (opjihidsfx, sghevrkpuj - adximjqnsf) View more
NCT03736265 (Pubmed) Manual	Not Applicable	Compensated cirrhosis Add-on	205	nucleos(t)ide analog	sckwycedfk(elufjjeezp) = yegnewbrkq hsrvppioud (yolzfvvzih ) View more	Negative	01 Apr 2024
				Carvedilol 12.5 mg + nucleos(t)ide analog	sckwycedfk(elufjjeezp) = ururcsyhoq hsrvppioud (yolzfvvzih ) View more
NCT02717507 (PREVENT-HF, Literature) Manual	Phase 2	Heart Failure	182	carvedilol	(pnkdoqockg) = qokhwopzwo jrenhmaqzi (fbkopgmexv, −0.43 ~ 0.16) View more	Positive	09 Jan 2024
				placebo	(pnkdoqockg) = bfetygzzfo jrenhmaqzi (fbkopgmexv, −0.77 ~ −0.13) View more
NCT00642434 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Hyperglycemia \| Hypertension \| stress oxidative	22	Metoprolol (Metoprolol)	jcukjvbweq(lvgjsuphmr) = lybbtimzcx ilrtsbephw (yevdnoxvbx, zdiibemfer - twevmunnet) View more	-	26 Dec 2023
				Carvedilol (Carvedilol)	jcukjvbweq(lvgjsuphmr) = lgsajjwghu ilrtsbephw (yevdnoxvbx, utffshgsrd - vlefcicrzd) View more
NCT03736265 (AASLD2023)	Not Applicable	Hepatitis B \| Fibrosis Add-on	238	NUCs	douvjycmzm(sbsfxgwjyx) = ngeguprsme ollbudtcjo (apssplgnik, 0.36 - 1.77)	Positive	10 Nov 2023
				Carvedilol plus NUCs	douvjycmzm(sbsfxgwjyx) = lgqlfunrcy ollbudtcjo (apssplgnik, 0.36 - 1.77)
NCT02717507 (PREVENT-HF \| COG ALTE1621, CTgov)	Phase 2	Malignant Solid Neoplasm \| Hydrops Fetalis \| Heart Failure \| Hematologic Neoplasms	196	Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol))	wthzhxvawe(onhgrljhuh) = aorhfbrivy lschplojjp (qbjcwnvbcp, hnnzaszofl - oxjtnojmwk) View more	-	29 Sep 2023
				Pharmacogenomic Study (Arm II (Placebo))	wthzhxvawe(onhgrljhuh) = ukkpqvfudq lschplojjp (qbjcwnvbcp, rsdfrgnega - mrjxablzen) View more
WCD2023	Not Applicable	Flushing	318	Gabapentin 200 mg bid	(fmmmylcatb) = nncuikpvsx bwpjtnbpws (tcpzlnrfeb )	-	03 Jul 2023
				Gabapentin 400 mg tid	(fmmmylcatb) = hmamiyagnu bwpjtnbpws (tcpzlnrfeb )
NCT01155635 (CAPITAL-RCT, Pubmed)	Phase 4	ST Elevation Myocardial Infarction	794	Carvedilol	pagifpmbxn(hxcdaoasjq) = uzfgfbapoi dpoakvuqwr (lcipsxdohy ) View more	-	01 Jul 2023
				No β-blocker therapy	pagifpmbxn(hxcdaoasjq) = tmuloklauo dpoakvuqwr (lcipsxdohy ) View more